Partnership to Produce Therapeutic Proteins

(also in Montreal).

Expression and purification costs are important components of biomanufacturing expenditures and are known as key bottlenecks of the bioprocessing industry. The new alliance will provide an integrated, turnkey service to better serve the requirements of large pharmaceutical companies, smaller biotech companies, and research groups. The alliance will use proprietary technologies already developed by NCR-BRI and ProMetic for solving bioprocess challenges. The two parties will share the revenues generated from the services provided and royalties on sales equally.

"ProMetic's proven track record as a key developer of new technologies in the downstream processing area allows NRC to increase its scientific and technological capabilities in the field of therapeutic proteins,” remarked Dr. Michael Desrochers, director general, NRC-BRI. "This objective is of great importance to NRC's biotechnology program.”




Related Links:
Canadian National Research Council's Biotechnology Research Inst.
ProMetic